Jasmeer P Chhatwal,Stephanie A Schultz,Eric McDade,Aaron P Schultz,Lei Liu,Bernard J Hanseeuw,Nelly Joseph-Mathurin,Rebecca Feldman,Colleen D Fitzpatrick,Kathryn P Sparks,Johannes Levin,Sarah B Berman,Alan E Renton,Bianca T Esposito,Maria Vitoria Fernandez,Yun Ju Sung,Jae Hong Lee,William E Klunk,Anna Hofmann,James M Noble,Neill Graff-Radford,Hiroshi Mori,Steven M Salloway,Colin L Masters,Ralph Martins,Celeste M Karch,Chengjie Xiong,Carlos Cruchaga,Richard J Perrin,Brian A Gordon,Tammie L S Benzinger,Nick C Fox,Peter R Schofield,Anne M Fagan,Alison M Goate,John C Morris,Randall J Bateman,Keith A Johnson,Reisa A Sperling

Abstract:BACKGROUND: Insights gained from studying individuals with autosomal dominant Alzheimer's disease have broadly influenced mechanistic hypotheses, biomarker development, and clinical trials in both sporadic and dominantly inherited Alzheimer's disease. Although pathogenic variants causing autosomal dominant Alzheimer's disease are highly penetrant, there is substantial heterogeneity in levels of amyloid β (Aβ) between individuals. We aimed to examine whether this heterogeneity is related to disease progression and to investigate the association with mutation location within PSEN1, PSEN2, or APP.METHODS: We did cross-sectional and longitudinal analyses of data from the Dominantly Inherited Alzheimer's Network (DIAN) observational study, which enrols individuals from families affected by autosomal dominant Alzheimer's disease. 340 participants in the DIAN study who were aged 18 years or older, had a history of autosomal dominant Alzheimer's disease in their family, and who were enrolled between September, 2008, and June, 2019, were included in our analysis. 206 participants were carriers of pathogenic mutations in PSEN1, PSEN2, or APP, and 134 were non-carriers. 62 unique pathogenic variants were identified in the cohort and were grouped in two ways. First, we sorted variants in PSEN1, PSEN2, or APP by the affected protein domain. Second, we divided PSEN1 variants according to position before or after codon 200. We examined variant-dependent variability in Aβ biomarkers, specifically Pittsburgh-Compound-B PET (PiB-PET) signal, levels of CSF Aβ1-42 (Aβ42), and levels of Aβ1-40 (Aβ40).FINDINGS: Cortical and striatal PiB-PET signal showed striking variant-dependent variability using both grouping approaches (p<0·0001), despite similar progression on the clinical dementia rating (p>0·7), and CSF Aβ42 levels (codon-based grouping: p=0·49; domain-based grouping: p=0·095). Longitudinal PiB-PET signal also varied across codon-based groups, mirroring cross-sectional analyses.INTERPRETATION: Autosomal dominant Alzheimer's disease pathogenic variants showed highly differential temporal and regional patterns of PiB-PET signal, despite similar functional progression. These findings suggest that although increased PiB-PET signal is generally seen in autosomal dominant Alzheimer's disease, higher levels of PiB-PET signal at an individual level might not reflect more severe or more advanced disease. Our results have high relevance for ongoing clinical trials in autosomal dominant Alzheimer's disease, including those using Aβ PET as a surrogate marker of disease progression. Additionally, and pertinent to both sporadic and autosomal dominant Alzheimer's disease, our results suggest that CSF and PET measures of Aβ levels are not interchangeable and might reflect different Aβ-driven pathobiological processes.FUNDING: National Institute on Aging, Doris Duke Charitable Foundation, German Center for Neurodegenerative Diseases, Japanese Agency for Medical Research and Development.

De novo deleterious genetic variations target a biological network centered on Aβ peptide in early-onset Alzheimer disease

Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing

APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Hypothesis-based investigation of known AD risk variants reveals the genetic underpinnings of neuropathological lesions observed in Alzheimer's-type dementia

Extremely rare CNVs contributing to Alzheimer disease risk: a case-control association analysis of exome sequencing data from 22,319 individuals

Analysis of Alzheimer's disease associated deleterious non-synonymous single nucleotide polymorphisms and their impacts on protein structure and function by performing in-silico methods

Targeted sequencing on neurodegenerative genes identified novel causal and risk variants of familial Alzheimer's disease

Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer's disease profile and possible mechanisms of disease protection

Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer’s disease profile and possible mechanisms of disease protection

Clinical and genetic characteristics in a central-southern Chinese cohort of early-onset Alzheimer's disease

Two Novel Pde11a Genetic Variants Increase Tau Phosphorylations in Early-onset Alzheimer's Disease

Whole Exome Sequencing Analyses Identified Novel Genes for Alzheimer's Disease and Related Dementia

Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study

Lessons from genetic studies in Alzheimer disease

Two Novel Mutations and a De Novo Mutation in PSEN1 in Early-onset Alzheimer’s Disease

Exome Sequencing Revealed PDE11A as a Novel Candidate Gene for Early-Onset Alzheimer's disease

The Possible Pathogenic and Protective Genetic Factors

Identification of a specific APOE transcript and functional elements associated with Alzheimer's disease

Functional Connectivity Alterations in Asymptomatic Familial Early-Onset Alzheimer's Disease Caused by APP Duplication

Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease

Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk